{"id":"W4294940241","doi":"10.1016/j.jtho.2022.07.592","title":"EP08.01-020 Phase 2 Platform Trial of Anti-TIGIT GSK’859A/EOS-448 + Anti-PD-1 Dostarlimab in Non-small Cell Lung Cancer (NSCLC)","year":2022,"lang":"en","type":"article","venue":"Journal of Thoracic Oncology","topic":"Cancer Immunotherapy and Biomarkers","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":false,"ca_institutions":"William Osler Health System","funders":"","keywords":"TIGIT; Medicine; Lung cancer; Oncology; non-small cell lung cancer (NSCLC); Internal medicine; Cancer research; Lung; Cancer; A549 cell; Immunotherapy","routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false,"invisible_to_affiliation_only":false},"retraction":null,"screen":null,"direct_labels":[],"prediction":{"model_version":"metacan-v3-hybrid-931329e0061c","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.001219106,0.001468042,0.001311764,0.0003208453,0.000300374,0.001349529,0.000825829,0.001208165,0.01102403],"category_scores_gemma":[0.0005624005,0.0005788286,0.001706343,0.0002362277,0.0006528514,0.00099899,0.000480238,0.004009596,0.003319724],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.001136048,"about_ca_system_score_gemma":0.001396529,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.001338389,"about_ca_topic_score_gemma":0.004828134,"domain_scores_codex":[0.9996891,0.0000953316,0.00001109602,0.00005779077,0.00003055454,0.0001162466],"domain_scores_gemma":[0.9997334,0.00003026669,0.0000336128,0.00002820748,0.00002090776,0.0001537],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","study_design_scores_codex":[0.6408647,0.03316687,0.004000079,0.001495692,0.002439417,0.0003798335,0.0002315841,0.004323918,0.04729173,0.001680438,0.04639243,0.2177331],"study_design_scores_gemma":[0.7193285,0.2451416,0.01099647,0.0001110845,0.0007436505,0.0004527522,0.00007577144,0.002247634,0.003905055,0.0009543231,0.01599855,0.00004452946],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9591886,0.003457514,0.001031864,0.00323744,0.001129464,0.003862374,0.009888713,0.0005494439,0.01765454],"genre_scores_gemma":[0.9275833,0.003093435,0.003608757,0.004828291,0.0004708509,0.004601001,0.02280347,0.0001547099,0.03285616],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.01102403,"threshold_uncertainty_score":0.03687906,"prediction_status":"machine_predicted_unvalidated"},"machine_scores":{"provisional":true,"baseline":true,"maturity_gate_passed":false,"score_opus":0.02975657000530349,"score_gpt":0.4036816848237961,"score_spread":0.3739251148184926,"validation_status":"score_only:v0-immature-baseline","note":"Baseline scores from an immature model (maturity gate not passed). Scores rank; they never assert a category."}}